t
N4 Pharma plc announced that a special resolution to change its name to Thalia Therapeutics plc was passed at its General Meeting held on March 17, 2026. The name change has taken effect following registration at Companies House and will become effective on the London Stock Exchange on March 18, 2026. The Company's TIDM will change from N4P to THAT, while its LEI (213800OIN8T68PM7HK77), ISIN (GB00BYW8QM32), and SEDOL (BYW8QM3) will remain unchanged.
| Date | 17 Mar 2026 |
| Time | 12:14:38 |
| Category | AGMs and other meetings |
| ID | 9980W |
17 March 2026
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of General Meeting and Change of Name to Thalia Therapeutics plc
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at the General Meeting of the Company held earlier today, the special resolution to change the Company's name to Thalia Therapeutics plc was duly passed.
The Company further announces that the change of name has now taken effect following registration at Companies House and will become effective on the London Stock Exchange tomorrow, 18 March 2026.
The Company's TIDM will change from N4P to THAT. The Company's LEI (213800OIN8T68PM7HK77), ISIN (GB00BYW8QM32) and SEDOL (BYW8QM3) will remain unchanged.
Shareholders should note that their holdings of ordinary shares in the Company will not be affected by the change of name. Existing share certificates should be retained as they remain valid for all purposes and new share certificates will not be issued.
Pursuant to AIM Rule 26, the proxy votes received in relation to the resolution will be made available on the Company's website, and the Company's website will be updated from tomorrow at https://www.thaliatx.com
Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, commented:
"The change of name to Thalia Therapeutics reflects our strategic evolution into a therapeutics-focused biotechnology company. With a growing RNA therapeutics pipeline and our proprietary Nuvec® delivery platform, we believe the Company is well positioned to advance innovative treatments and deliver long-term value for shareholders."
- Ends -
For more information please contact:
|
N4 Pharma plc Dr Chris Britten, Chairman Luke Cairns, Executive Director Dr David H Solomon, CEO |
Via Thalia Investor Hub |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Limited Investor Relations Sarah Hollins |
Tel: +44 (0)20 7183 2463
|
About Thalia Therapeutics plc
Thalia Therapeutics plc, formerly N4 Pharma plc, is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.
RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.
Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
For further information visit www.thaliatx.com